T several protein-protein and enzymatic interactions. For example, C4-binding protein interacts with both complement component C4 and protein S, which functions in the anticoagulant protein C-thrombomodulin Vitronectin interferes with assembly of the terminal C9 complex' and can modulate the function of heparin cofactor IL4 C1 esterase inhibitor is a principal inhibitor of activated complement component C1, and inhibits factor XIJa, kallikrein, and factor XIa, as
Further, complement components C5b-9 accelerate the rate of platelet-catalyzed blood clotting, apparently by increasing the ability of the platelet membranes to support prothrombinase (factor Va-factor Xa) assembly."*" While these examples show that multiple interactions intertwine the coagulation and complement reaction schemes, we postulate that complement fixation at the membranes of cells may directly initiate coagulation by evoking tissue factor expression.
Tissue factor is a membrane protein that serves as the essential cofactor for factor VI1 in the initiation of coagulation via factors IX and X.I2-l4 Some cells, such as and cells of the g l o m e r~l u s ,~~~'~ may routinely contain tissue factor. Studies with cells in culture have established that "healthy" cells may express tissue factor functional activity, but the procoagulant activity increases dramatically upon cell "damage" or disrupti~n.'~.'~ While monocytes and endothelial cells are believed to contain no tissue factor in the absence of inflammatory stimuli, complement activation may induce synthesis of tissue factor by these cells, possibly in response to fragments of C5.20-22 Insofar as complement fixation a t the cell surface can result in "membrane damage," there may be a direct and immediate link between the complement and coagulation cascades when they meet at the surface of a cell containing tissue factor. To examine this possibility, we conducted the following studies.
MATERIALS AND METHODS
Human fibroblast lines used in this study (GM5756 and GM5758) were obtained from the National Institute of General Medical Sciences (NIGMS) Human Genetic Mutant Cell Repository. They were maintained in 25 cmz T-flasks in Dulbecco's modified Eagle's medium (DMEM) with high glucose (GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (Dutchland, Denver, PA), antibiotics, and NCTC 109, as previously detailed." The cells were dispersed in trypsin-EDTA (Flow Laboratories, McLean, VA) and activity, which correlated with cytolysis, as measured by 51 -chromium release. Therefore, complement fixation on the cell surface can have a direct and immediate stimulatory effect on the coagulation cascade at the point of its initiation, with formation of a fibrin clot requiring only three consecutive proteolytic reactions after immunologically mediated cell damage. 0 1990 by The American Society of Hematology.
seeded into 96-well microtiter plates at least 24 hours before beginning each experiment.
Experiments were begun by replacing the complete culture medium with DMEM lacking phenol red (GIBCO) and containing only bovine serum albumin at 40 mg/mL (DMEM-BSA). The fibroblasts were incubated with sodium 5 1-chromate (Amersham) at 100 pCi/106 cells (1 Ci = 3.7 x 10" Bq) for 3 hours. The labeled cells were washed five times with DMEM-BSA and then incubated with 100 pL serial dilutions of antibody. After 45 minutes, 50 pL of rabbit complement (newborn rabbit serum; Cedar Lane Laboratories, Hornsby, Ontario) diluted 1/10 in DMEM-BSA was added to each culture well. Complement activation was allowed to proceed for 2.25 hours at 37OC. The cell supernatants were sampled and counted fqr chromium released from the cells, residual reaction media was drained from the cells, and the wells were rinsed and assayed for tissue factor activity.
Chromium release from the cells was determined by removing 100 pL of the culture supernatant from each well and measuring radioactive 51-chromium in a Beckman Gamma 5500 counter (Beckman Instruments, Irvine, CA). The machine background was recorded for each experiment. In addition, supernatants were collected from cells maintained in DMEM-BSA without antibody or complement to determine the spontaneous release of chromate, and other supernatants were sampled after detergent lysis (1% Tween-20) of the cells for determination of total chromium label in the cell cultures.
Before determination of tissue factor activity, the remaining 50 pL of DMEM-BSA was drained from the wells. The cells were gently rinsed with 100 pL of reaction buffer (0.05 mol/L Tris, 0.1 mol/L NaC1, 0.02% sodium azide, pH 7.6 with 1 mg/mL BSA) and drained, and 60 pL of reaction buffer was added to each culture well. Tissue factor activity was determined using a microplate reader- School, New York, NY). The factor VIIa and factor X were used at 1 nmol/L and 100 nmol/L, respectively, in each microplate well. This assay has been used to measure tissue factor activity on intact cells,24 and the relative activity measured and expressed in terms of A405/min2 (x106) has been shown to be extremely sensitive to changes in known concentrations of tissue factor. 25 The rabbit antithymocyte globulin (RATG) was prepared according to Bieber et alZ6 and Davis et ai?' and provided by Dr Doug Smith (University of Nebraska Medical Center). BaSO, (10 mg/ mL) was added for 1 hour and removed by centrifugation to adsorb most of the factor X(a) and factor VII(a) from the RATG. This antiserum was used in these experiments because of its availability and proven strong immunologic reactivity with surface antigens of human cells. Additionally, since RATG was developed using thymocytes as antigen, no antibodies against human tissue factor were present.
Human brain "thromboplastin" was prepared as a source of crude tissue factor using the protocol described for bovine brain.'* The 
RESULTS
Physical disruption of cells by freeze-thaw cycles or sonication clearly elevates the tissue factor activity of cultured fibroblasts, but procedures such as these are, in general, not very relevant to biological processes. Immunologic damage to cells, mediated by antibodies and complement, is a much more relevant physiologic process that has not been directly evaluated for immediate "damage"-related effects on tissue factor activity. We hypothesized that antibody-mediated complement fixation, which caused measurable injury to cultured fibroblasts, would also cause an increase in tissue factor activity. To test this hypothesis, we have used a rabbit antibody directed against human cells and rabbit complement, which has potent lytic activity when directed against human cells. Incubation of human fibroblasts with rabbit antibody against human thymocytes ( RATG)26*27 followed by complement produced significant release of chromium from the cells. Measurements of factor X activation by the same cells in the presence of factor VIIa revealed a strong correlation between the amount of chromium released (and inferred cytolysis) and the amount of tissue factor activity expressed by the cells. As shown in Fig  1A and B, both tissue factor activity and chromium release were dependent on the antibody concentration and the presence of complement. As expected by their similar dependencies on antibody concentration, tissue factor activity and cytolysis were highly correlated (Fig 1C) ( r values for three experiments ranged from .8457 to .9770).
An enzyme-linked immunosorbent assay (ELISA) conducted on cell cultures with antibodies against beta-2-microglobulin (DAKO, Santa Barbara, CA) demonstrated that very little of this antibody bound to the cells. Incubation with this antibody followed by complement produced little chromium release from the cells and, similarly, little increase in tissue factor activity. These experiments showed that, in the absence of measurable antibody binding to the cells, no increase in tissue factor activity or antibody-related chromium release was observed in the presence of complement.
Since the complement source and antibody were expected to contain some factor VI1 that might contribute to measured tissue factor activity, assays were conducted to ascertain the presence of enzymatic activities and the extent to which they could influence our results. As shown in Table 1 , both the complement source and the antibody contained some factor VII(a) activity, but little or no factor X activity, and neither produced direct hydrolysis of the chromogenic factor Xa substrate. The heat-treated complement source retained its factor VII(a) activity ("stable factor") but no longer retained complement activity. The additional factor VI1 increased the measured tissue factor activity less than 15% and should contribute even less in the experiments that included a buffer rinse before tissue factor assay. Equally important, neither reagent inhibited the activity of added tissue factor.
The heat-treated complement served as a reagent to verify the dependence of tissue factor activity increase on the action of complement. Aliquots of reconstituted newborn rabbit serum were warmed to 56OC and maintained at that temperature for 10 to 60 minutes. Other aliquots were held on ice. Fibroblast cultures incubated with RATG were treated with the various complement aliquots and evaluated for chromium release and tissue factor activity. As shown in Fig 2A, chromium release was virtually eliminated by the heat inactivation of the complement, while the unheated complement again produced antibody-dependent cytolysis. Tissue factor increased in an antibody-dependent manner in the presence of active complement, but remained at much lower levels in cells treated with the inactivated complement ( Fig  2B) . There was a small but significant antibody-dependent increase in tissue factor activity in the cells treated with complement heated for only 10 minutes (coefficient of regression = 1.13, t = 5.84, df = 12), even though chromium release was not significantly related to antibody concentration with this complement (coefficient of regression = 0.4, t = 0.88, df = 12). This may reflect the relative sensitivities of these two assays. Alternatively, some tissue factor increase may occur in response to activation of complement a t sublytic levels. The remaining treatments (no complement and complement heated for 60 minutes) did not produce antibody-dependent increases in tissue factor activity or chromium release. Overall, tissue factor activity correlated strongly with cytolysis (Fig 2C) , and increased tissue factor activity was clearly related to complement fixation. The hypothetical model under examination presumed the presence of tissue factor in the cell membranes in a low activity state that must become more active in response to antibody-dependent activation of complement and consequent membrane damage. Further validation of this model required demonstration of a temporal relationship between complement action and tissue factor expression. To this end, we conducted a final series of experiments in which antibody and complement were added at the same time, and the cultures were evaluated for cytolysis and tissue factor activity a t varied times thereafter. The details of this experiment and results are shown in Increased tissue factor activity was demonstrable before released chromium (Fig 3, columns 5 and 6, corresponding to 35 or 39 minutes in Fig 4A through  D) , indicating that measurable tissue factor increases preceded the measurable release of chromium. Wigzel13' showed that chromium release subsequent to complement damage occurred in two stages after an initial lag, and is slow relative to the occurrence of cell damage. The results shown in Figs 3 and 4, considered with Wigzell's findings, are consistent with our conclusion that tissue factor activity increases in re- sponse to complement-mediated membrane damage, and chromium is released relatively slowly after membrane damage. This observation may be somewhat exaggerated by differences in the sensitivities of tissue factor and chromium determinations. Measurable increases in tissue factor activity were observed between 20 and 40 minutes after addition of antibody and complement. At the highest concentrations of antibody, tissue factor activity reached its maximum levels within about 1 hour, whereas chromium release continued throughout the experiment. This suggests that either maximum amounts of complement were fixed or tissue factor was maximally increased within this period a t high concentrations of RATG. Alternatively, microscopic examination of the cells showed severe damage in cultures with the greatest chromium release. Tissue factor may have been lost when these wells were rinsed before assay. Such losses would diminish the correlation of cytolysis and tissue factor activity, a correlation that remains convincing a t each time point where both responses are measurable even with this qualification (Fig 4E and F) .
By selecting RATG and rabbit serum as the sources of antibody and complement, respectively, we intentionally conducted experiments that were expected to cause immune damage to human cells in order to test our hypothesis. We have recently conducted additional experiments in which human serum was used as the complement source. Even though human complement should be less lytic than rabbit complement when tested against human cells, these experiments have also shown increased tissue factor activity that is dependent on both antibody concentration and the presence of complement.
While the molecular mechanisms by which tissue factor activity is increased after complement activation remain to be elucidated, the observation itself may be particularly relevant to pathologic processes in which fibrin deposition is colocalized with immune complexes, or in conditions in which the presence of specific antibodies is correlated with thrombosis. Recent reports that complement fixation is
DISCUSSION
We have shown that increased tissue factor activity is one consequence of complement fixation on tissue factor-bearing cells. While reactions of complement activation preceding cytolysis may be responsible for the stimulation of tissue factor expression, the observed stimulation correlates strongly with chromium release, which is presumed to measure cytoly~is.'~ These results support our hypothesis that complement fixation on cells may directly trigger blood coagulation at a principal initiation reaction, with no requirement for induction of tissue factor synthesis before expression. (Fig  3, A and C ) and C and D are derived from the experiment conducted 72 hours after plating (Fig 3, B and D) . In A, 6, C, and D, the varied symbols correspond to RATG dilutions of cated in tissue factor-expressive malignancies, since the immune cytolysis can initiate coagulation and, hence, contribute to the production of local fibrin, which can isolate and further protect the abnormal cells from the host r e~p o n s e .~' .~~
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